Purpose: To describe a case of anaphylactic reaction during implantation of the Ovation Abdominal Stent Graft System in a patient treated for abdominal aortic aneurysm (AAA). Case Report: An 82-year-old man with a 5.3-cm asymptomatic AAA underwent endovascular repair using an Ovation stent-graft. Polymer was infused into the inflatable rings of the aortic body under continuous angioscopy, but the rings were not filled, even though the entire amount of the polymer was administered. Simultaneously, the patient presented with a severe anaphylactic reaction resulting in cardiopulmonary arrest. He was successfully resuscitated, but the procedure was abandoned; the patient refused any further treatment. Conclusion: A rupture of the Ovation main body’s polymer-filled rings may lead to extremely severe anaphylactic reaction.
GreenhalghRMBrownLCKwongGP. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet. 2004;364:843–848.
2.
MehtaMValdésFENolteT. One-year outcomes from an international study of the Ovation Abdominal Stent Graft System for endovascular aneurysm repair. J Vasc Surg. 2014;59:65–73.e1-3.
MoulakakisKGDalainasIKakisisJ. Current knowledge on EVAR with the ultra-low profile Ovation Abdominal Stent-graft System. J Cardiovasc Surg (Torino). 2012;53:427–432.
5.
De DonatoGSetacciFSirignanoP. Ultra-low profile Ovation device: is it the definitive solution for EVAR?J Cardiovasc Surg (Torino). 2014;55:33–40.
6.
GeorgakarakosETrellopoulosGKontopodisN. The inflatable-rings fixation mechanism of the Trivascular Ovation Stent Graft System: every revolution comes at a price!. J Cardiovasc Surg (Torino). [published online March20, 2014]
7.
NanoGMazzaccaroDStegherS. Early experience with Ovation endograft system in abdominal aortic disease. J Cardiothorac Surg. 2014;9:48.
8.
KnopKHoogenboomRFischerD. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010;49:6288–6308.
Chanan-KhanASzebeniJSavayS. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol. 2003;14:1430–1437.
11.
SzebeniJ. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216:106–121.
12.
CalvoDde la HeraJMLeeDH. Contrast echocardiography and clinical safety [in Spanish]. Rev Esp Cardiol. 2006;59:399–400.
